In the article by Gorecki et
al. (), the authors reported that maleimides irreversibly
inhibited both the African malaria mosquito (Anopheles gambiae) Ace-paralogous acetylcholinesterase (aka agAP-AChE[1]) bearing a free Cys and the human counterpart
devoid of the Cys and concluded that “Cys-targeted insecticides
against A. gambiae acetylcholinesterase are neither
selective nor reversible inhibitors”. This conclusion is problematic
for at least six reasons.A prerequisite to claim that maleimidePM20[2] does not conjugate with the agAP-AChE
Cys is to confirm that the Cys is not oxidized. However, in the Gorecki
article, no evidence was provided to show that the Cys in their agAP-AChE
was active for conjugation.In the Gorecki article, their agAP-AChE
was claimed to be “in very good correlation” with the
reported agAP-AChE[3] that was used in ref (2). However, only KM was reported for their agAP-AChE. Their omission
of kcat, which is also needed for enzyme
comparison, raises concerns with their specific enzyme activity. Their
enzyme could be reasonably active (like crude extracts) and suitable
for certain inhibitor characterizations but unsuitable for the kinetic
characterization of PM20 described in ref (2).In the Gorecki article, 10 μM PM20 and 10 μM
paraoxon (rather than 1 nM PM20 and 200 nM paraoxon in
ref (2)) showed no
agAP-AChE activity recovery after dialysis.
Using higher inhibitor concentrations here would prompt for determining
the specific enzyme activity at the time when the assay was performed.
However, no specific enzyme activity was reported in the Gorecki article.
This substantiates the activity concerns above.Potential irreversible inhibitors
can be identified by their progressive inhibition
from reversible inhibitors that exhibit constant inhibition
in a time-course experiment. This requires controls at proper concentrations
to define a period of time over which the progressive inhibition can be observed. Using high inhibitor concentrations
can make the progressive inhibition period too short
to practically measure the enzyme activity over the period. In ref (2), 6 nM PM20, 300 nM PMS20, and 700 nM paraoxon showed 20–30%
agAP-AChE inhibition after 3 min, and then PM20 and paraoxon
showed progressive agAP-AChE inhibition over the
3–15 min period, whereas PMS20 showed constant 20% agAP-AChE inhibition over the same period,
wherein PMS20 (a maleimide-free analog of PM20) and paraoxon (known to conjugate with the catalytic Ser of cholinesterases)
were controls to show respective constant and progressive inhibitions. In the Gorecki article, 800 nM PM20 exhibited nearly constant agAP-AChE
inhibition over the 3–15 min period in their experiment without
using known inhibitors (e.g., PMS20 and paraoxon) to
show that their experimental conditions are suitable to observe constant and progressive inhibitions. The
use of a high PM20 concentration and the lack of controls
raise concerns about their study design.The conclusion of the Gorecki article
regarding inhibitor selectivity is IC50-based and contradicts
the textbook[4] on irreversible inhibitor
evaluation using kinact/KI: “An important point to realize here is that
attempts to quantify the relative potency of irreversible enzyme inactivators
by more traditional parameters, such as IC50 values, are
entirely inappropriate because these values will vary with time, in
different ways for different compounds. Hence the SAR derived from
IC50 values, determined at a fixed time point in the reaction
progress curve, is meaningless and can be misleading in terms of compound
optimization.”Maleimides are nonselective alkylating
agents that have never been used as insecticides. PM20 was intended only for mass spectrometric evidence for Cys conjugation
with agAP-AChE.[2] Equating maleimides with
“Cys-targeted insecticides” in the Gorecki article is
improper and misleading.
Authors: Lukas Gorecki; Rudolf Andrys; Monika Schmidt; Tomas Kucera; Miroslav Psotka; Barbora Svobodova; Veronika Hrabcova; Vendula Hepnarova; Petr Bzonek; Daniel Jun; Kamil Kuca; Jan Korabecny; Kamil Musilek Journal: ACS Med Chem Lett Date: 2019-11-26 Impact factor: 4.345